Ultracentrifuge for separating small molecules, compounds, and vesicles
Official title: Ultracentrifuge for Separation of Small Molecules, Compounds, and Vesicles
Funded at Universidad Central Del Caribe · NIH-11364636 · Data updated 2026-11-12
A new ultracentrifuge will be bought for a shared core facility to speed up high-precision separation of tiny particles and molecules for multiple biomedical research projects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Universidad Central Del Caribe NIH-funded |
| Lab location | 1 site (Bayamon, United States) |
| Project start | July 3, 2026 |
| Project end | July 2, 2027 |
| Funding year | 2026 |
| Award (this year) | $148,607 |
| NIH project number | 1S10GM164800-01 |
| Project ID | NIH-11364636 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable to patient participation; this is a core facility improvement that benefits researchers and, ultimately, patients through faster science.
✕Less likely to help
Patients are not directly enrolled or involved in this grant; benefits arise from enhanced research capacity.
What this research studies
Researchers at Universidad Central Del Caribe need a high-performance ultracentrifuge to rapidly and precisely separate subcellular particles, proteins, and small molecules. The instrument will be housed in the Common Instrumentation Area and Services (CIAS) and shared among faculty, postdocs, and students across departments. By providing up-to-date capabilities, this core facility will reduce dependence on external labs and outdated equipment, and it will support molecular, oncological, natural-based, and immunological research. The project emphasizes updating infrastructure to accelerate discoveries and training in modern biochemical techniques. This grant funds a specific instrument to address a critical gap in core facilities at the institution.
Why it matters
Potential benefit: If successful, researchers will gain timely access to advanced centrifugation capabilities that can accelerate discoveries in multiple biomedical areas and improve training in essential lab methods.
How similar studies have gone: Instruments like high-performance ultracentrifuges have historically improved research throughput and methodological training in biomedical labs.
Where this research is happening
-
Universidad Central Del Caribe
Bayamon, United States Active
Researchers
- Principal investigator: Alvarez, Eduardo — Universidad Central Del Caribe
- Study coordinator: Alvarez, Eduardo
Related research
Other NIH-funded projects on the same topics.
-
Targeted breast cancer treatment using a natural product to block cancer cell survival
A patient-friendly look at a grant that supports testing a natural compound that may stop a tough type of breast cancer from thriving.
-
Blocking Pyk2 to help immune therapy work better for glioblastoma
Seeing if stopping a protein called Pyk2 can make immune checkpoint drugs (like PD-L1 blockers) work better for people with glioblastoma.
-
Beta-amyloid build-up in the brain for Parkinson's disease
This research explores how a protein called amyloid beta, often linked to Alzheimer's, builds up in the brains of people with Parkinson's disease, especially when dementia develops.
-
Understanding how beta-amyloid builds up in the brain of Parkinson's disease patients
This study is looking at how a substance called amyloid beta builds up in the brains of people with Parkinson's disease as they start to experience dementia, and it aims to find out how this buildup happens and what role blood cells and inflammation play in the process.
-
Investigating how ergosterol peroxide can selectively inhibit aggressive breast cancer
This study is looking at how a natural compound from fungi, called ergosterol peroxide, can help fight triple-negative breast cancer by killing cancer cells without harming normal cells, with the hope of creating a new treatment option for patients facing this tough type of cancer.
-
Blocking Pyk2 to improve immune therapy for aggressive brain cancer
This study is looking at how blocking a protein called Pyk2 might help make glioblastoma, a tough brain cancer, more sensitive to treatments that use the immune system, so that patients can have better responses to their therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.